DIVO vs XBI
Amplify CWP Enhanced Dividend Income ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.56% for DIVO.
- • DIVO pays a higher dividend yield (2.26%).
Side-by-side metrics
| Metric | DIVO | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.56% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.26% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $7.19B | $10.73B |
YTD return | 6.37% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.56 | 1.10 |
P/E ratio | 24.82 | — |
Last price | $46.27 | $164.28 |
Inception | — | — |
Issuer | Amplify | State Street |
DIVO top holdings
| CAT | Caterpillar Inc | 6.98% |
| AAPL | Apple Inc | 5.10% |
| MSFT | Microsoft Corp | 4.93% |
| JPM | JPMorgan Chase & Co | 4.86% |
| GS | The Goldman Sachs Group Inc | 4.59% |
| AXP | American Express Co | 4.52% |
| TJX | TJX Companies Inc | 4.43% |
| SOFR | Amplify Samsung SOFR ETF | 4.31% |
| AMGN | Amgen Inc | 4.19% |
| CME | CME Group Inc Class A | 3.98% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About DIVO
DIVO (Amplify CWP Enhanced Dividend Income ETF) is Quality dividend payers with tactical covered calls. Managed by Amplify, the fund carries $7.2B in assets under management, an expense ratio of 0.56%, a dividend yield of 2.26%. Its largest holding is Caterpillar Inc (CAT), which represents 7.0% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 11.4%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.